Gemcitabine En bac hearing denied by CAFC


Gemcitabine method of use patent (5,464,826) was invalidated by U.S. District Court for the Eastern District of Michigan and affirmed by CAFC (Order).

Eli Lilly filed petition for panel rehearing and en bac rehearing and it was supported by BIO members amici curiae. CAFC now denied the rehearing petitions (Order)

Note:

Eli Lilly has sued sandoz, DRL and Accord Healthcare recently on ‘826 patent

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Patent case. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s